cytarabine

Blinatumomab was administered after one cycle of high-dose methotrexate/cytarabine, resulting in MRD negativity after one cycle...Inotuzumab ozogamicin induced a second hematological remission with MRD negativity, although disease control was not durable. This case highlights the importance of repeat immunophenotypic and cytogenetic assessment at relapse after blinatumomab treatment.

P2, N=39, Recruiting, University of Maryland, Baltimore | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Jun 2026 --> Jun 2027

P2, N=120, Not yet recruiting, Peking University People's Hospital

P1, N=76, Active, not recruiting, Syndax Pharmaceuticals | Recruiting --> Active, not recruiting

The patient received high-dose cytarabine over three cycles, developed febrile neutropenia requiring amikacin, and was subsequently started on imatinib 400 mg in view of the BCR-ABL1 positivity. What makes this case worth reporting is the convergence of three issues that each present their own challenges: establishing a diagnosis of de novo AML rather than CML in blast crisis, managing an already aggressive disease made more so by a complex karyotype, and deciding on the role of tyrosine kinase inhibitors in a disease setting where their use is not yet standardized. Detailed cytogenetic workup proved critical in navigating all three.

She underwent therapy with rituximab, methotrexate, procarbazine, and vincristine followed by high-dose cytarabine, achieving temporary remission; however, relapse occurred 1 month after consolidation therapy. This case also suggests a potential therapeutic role for tirabrutinib in early-relapsing LC. https://thejns.org/doi/10.3171/CASE26337.

Synergism with doxorubicin (DOX) and other chemotherapeutic agents was quantified by combination index (CI) analysis using the Chou-Talalay method and spheroid culture assays...AAP similarly synergized with daunorubicin but not with etoposide or cytarabine, suggesting selectivity for ROS-inducing anthracyclines. These findings establish AMF-derived peptides as promising human-origin chemosensitizers capable of overcoming multidrug resistance in HMs through multi-targeted mechanisms. The ability to reduce anthracycline dosing while maintaining efficacy offers potential for minimizing cardiotoxicity and other dose-limiting adverse effects, warranting further preclinical development toward clinical translation.

P2, N=226, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=30, Completed, Australasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed

P2, N=148, Not yet recruiting, Shen yang

P1, N=50, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2026 --> Sep 2026

P2, N=216, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting